Gentamicin

證據等級: L5

預測適應症: 10 個

Gentamicin: From Bacterial Infections to Rheumatoid Arthritis

One-Sentence Summary

Gentamicin is a broad-spectrum aminoglycoside antibiotic clinically used to treat serious infections caused by gram-negative bacteria. The TxGNN model predicts it may have potential relevance to Rheumatoid Arthritis (RA), with 1 Phase 4 clinical trial and 20 publications retrieved — however, critical review reveals that virtually all evidence is indirect, reflecting gentamicin's use as a surgical infection prophylaxis in RA patients undergoing joint replacement, rather than as a disease-modifying agent for RA itself.

Quick Overview

Item	Content
Original Indication	Serious gram-negative bacterial infections (aminoglycoside antibiotic)
Predicted New Indication	Rheumatoid Arthritis
TxGNN Prediction Score	97.76%
Evidence Level	L3
Singapore Market Status	Not marketed
Number of Registrations	0
Recommended Decision	Hold

Why is This Prediction Reasonable?

Currently, detailed mechanism of action data is not available in the evidence pack. Based on established pharmacology, Gentamicin is an aminoglycoside antibiotic that binds to the bacterial 30S ribosomal subunit, disrupting mRNA decoding and causing bactericidal activity — primarily against aerobic gram-negative organisms. It has no established direct immunomodulatory or disease-modifying mechanism relevant to autoimmune inflammatory conditions such as RA.

Two indirect mechanistic hypotheses have been proposed: (1) bacterial antigens originating in the gut or synovial compartment may trigger and perpetuate RA autoimmunity, and antibiotic intervention could theoretically reduce immune stimulation; and (2) aminoglycosides may possess mild NF-κB inhibitory activity that could theoretically dampen inflammation — however, neither hypothesis has been clinically validated in an RA treatment context. Both remain highly speculative.

In practice, all retrieved clinical evidence pertains to gentamicin being used as an adjunct infection prophylaxis in RA patients undergoing total joint arthroplasty (via antibiotic-impregnated bone cement or collagen sponges), not as a treatment targeting RA disease activity itself. The high TxGNN score most likely reflects the strong co-occurrence of "Gentamicin" and "rheumatoid arthritis" in the biomedical literature due to this shared surgical context, rather than a genuine therapeutic signal for the underlying autoimmune disease.

Clinical Trial Evidence

Trial Number	Phase	Status	Enrollment	Key Findings
NCT00872066	Phase 4	Completed	243	Post-market surveillance study evaluating SmartSet® HV and SmartSet® GHV gentamicin-loaded bone cements in primary total hip arthroplasty; assessed performance via patient, clinical, and X-ray outcomes at regular intervals. Hip joint disease (including RA) was the indication for surgery. No RA disease-modification was assessed — relevance to direct RA treatment is Grade C (indirect).

Literature Evidence

PMID	Year	Type	Journal	Key Findings
14649677	2003	Clinical Study	J Chinese Med Assoc	Evaluated systemic antibiotics combined with gentamicin-impregnated bone cement in primary TKA for RA patients (n=60 knees); studied prevention of deep joint infection in the perioperative period — not a treatment for RA itself
41221316	2025	Systematic Review	Acta Ortopedica Brasileira	Synthesised clinical evidence on risk factors, prevention methods (including gentamicin-loaded cement), and treatment of periprosthetic infections in total hip arthroplasty; RA listed as one of the primary surgical indications
11233881	2001	Observational	Dtsch Med Wochenschrift	Microbiological and immunological monitoring in a polyarticular RA patient after multiple joint replacements; gentamicin used for perioperative infection management
33812255	2021	Animal Study	Int Immunopharmacol	Daphnetin (a drug clinically used to treat RA) was shown to ameliorate gentamicin-induced nephrotoxicity in mice via antioxidant mechanisms; highlights the RA–gentamicin nephrotoxicity interaction risk
32751547	2020	PK Study	Pharmaceutics	Pharmacokinetics of tofacitinib (RA treatment) were significantly altered in a gentamicin-induced acute renal failure rat model; demonstrates gentamicin nephrotoxicity as a clinically meaningful confounding factor in RA pharmacotherapy
33827581	2021	Case Report	Ann Clin Microbiol Antimicr	Helicobacter canis bacteremia in an RA patient on tofacitinib; illustrates the clinical context in which gentamicin may be used to manage atypical infections in immunosuppressed RA patients
7019786	1981	Case Report	NZ Med J	RA patient developed acute tubular necrosis following combined gentamicin and cefoxitin treatment; underscores the nephrotoxicity risk in RA patients receiving gentamicin
4579913	1973	Case Report	JAMA	Serratia septic arthritis was medically eradicated with antibiotic therapy (including gentamicin) in an RA patient; gentamicin used for superimposed bacterial infection, not for RA disease modification
40119266	2025	Case Report / Review	BMC Infect Dis	Septic shock from drug-resistant Edwardsiella tarda; gentamicin considered among treatment options for multi-drug resistant gram-negative infections, relevant to infection management in immunocompromised patients including those with RA
20374322	2009	Case Series	Int J Rheumatic Dis	Life-threatening cardiac tamponade in two RA patients on adalimumab; while unrelated to gentamicin, illustrates the infectious and extra-articular complication landscape in RA patients on biologics who may require antibiotic therapy

Singapore Market Information

Gentamicin is currently not registered in Singapore. No product authorizations are on record (total registrations: 0). This candidate would require a full regulatory filing with the Health Sciences Authority (HSA) before any clinical use in Singapore could be considered.

Safety Considerations

Please refer to the package insert for safety information.

Important contextual note: Although structured safety data was unavailable in this evidence pack, Gentamicin is well-established to carry significant risks of dose-dependent nephrotoxicity (proximal tubular injury) and ototoxicity (cochlear and vestibular damage), which are the primary barriers to systemic use. These risks are of particular concern in RA patients, who may have concurrent renal impairment or be on other nephrotoxic agents (e.g., NSAIDs, methotrexate). No drug-drug interaction data were returned from the database query.

Conclusion and Next Steps

Decision: Hold

Rationale: Despite a high TxGNN computational prediction score (97.76%), this signal is most likely driven by the high co-occurrence of gentamicin and rheumatoid arthritis in the surgical infection-prevention literature, rather than a genuine disease-modifying therapeutic relationship. No evidence was identified supporting gentamicin as a treatment for RA disease activity, and known nephrotoxicity and ototoxicity present significant safety barriers to chronic systemic use in this patient population.

To proceed, the following is needed:

Preclinical studies directly evaluating the effect of gentamicin (or its aminoglycoside class) on RA-relevant endpoints (synovial inflammation, autoantibody titres, cartilage protection in animal arthritis models)
Mechanistic characterisation of NF-κB inhibitory activity or microbiome-mediated immunomodulation in an RA-specific context
Investigation of novel delivery strategies (e.g., local intra-articular or topical formulations) that could circumvent systemic nephrotoxicity/ototoxicity if a disease-modifying signal is confirmed
Regulatory pathway assessment with HSA for Singapore registration, should preclinical evidence become supportive
Disclaimer

This content is for research purposes only and does not constitute medical advice. Clinical validation is required before any clinical application.